The association between negative symptoms, psychotic experiences and later schizophrenia: A population-based longitudinal study

Nomi Werbeloff, Bruce P. Dohrenwend, Rinat Yoffe, Jim Van Os, Michael Davidson, Mark Weiser

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Abstract

Background: Psychotic experiences are common in the general population, and predict later psychotic illness. Much less is known about negative symptoms in the general population. Method: This study utilized a sample of 4,914 Israel-born individuals aged 25-34 years who were screened for psychopathology in the 1980's. Though not designed to specifically assess negative symptoms, data were available on 9 self-report items representing avolition and social withdrawal, and on 5 interviewer-rated items assessing speech deficits, flat affect and poor hygiene. Psychotic experiences were assessed using the False Beliefs and Perceptions subscale of the Psychiatric Epidemiology Research Interview. Psychiatric hospitalization was ascertained 24 years later using a nation-wide psychiatric hospitalization registry. Results: After removing subjects with diagnosable psychotic disorders at baseline, 20.2%had at least one negative symptom. Negative symptoms were associated with increased risk of later schizophrenia only in the presence of strong (frequent) psychotic experiences (OR = 13.0, 9% CI: 2.1-79.4). Conclusions: Negative symptoms are common in the general population, though the majority of people with negative symptoms do not manifest a clinically diagnosed psychiatric disorder. Negative symptoms and psychotic experiences critically depend on each other's co-occurrence in increasing risk for later schizophrenia.

Original languageEnglish
Article numbere0119852
JournalPLoS ONE
Volume10
Issue number3
DOIs
StatePublished - 6 Mar 2015
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2015 Werbeloff et al.

Funding

Nomi Werbeloff, Bruce P. Dohrenwend, and Rinat Yoffe report no conflicts of interest in relation to the subject of this study. Jim van Os has received unrestricted investigator-led research grants or recompense for presenting his research from Eli Lilly, Bristol-Myers Squibb, Lundbeck, Organon, Janssen-Cilag, GlaxoSmithKline, AstraZeneca, Pfizer and Servier, companies that have an interest in the treatment of psychosis. Michael Davidson holds stocks in TGD and BiolineRx and has received research grant support and/or travel support and/or speaker fees and/or consultancy fees from JNJ, Pfizer, Lundbeck, Teva, BioLineRx, Eli Lilly, Sanofi-Aventis, Roche, GSK, Servier, Envivo, and Novartis. Mark Weiser has received research grant support and/or travel support and/or consultant fees and/or speaker fees from Eli Lilly, AstraZeneca, Janssen-Cilag, Pfizer, Lundbeck, Teva, BioLineRx, Sanofi-Aventis and Roche. The authors confirm that their declaration of competing interests does not alter their adherence to PLOS ONE policies on sharing data and materials.

FundersFunder number
BiolineRx
Eli Lilly and Company
Pfizer
AstraZeneca
GlaxoSmithKline
Novartis
Roche
Sanofi
Teva Pharmaceutical Industries
Cilag
Servier
H. Lundbeck A/S

    Fingerprint

    Dive into the research topics of 'The association between negative symptoms, psychotic experiences and later schizophrenia: A population-based longitudinal study'. Together they form a unique fingerprint.

    Cite this